Asia-Pacific Medical Device Registration: Market Comparison and Entry Strategy (2026)

Asia-Pacific Is the Fastest-Growing Medical Device Market — and the Most Complex to Enter

The Asia-Pacific medical devices market was valued at approximately $127.6 billion in 2025 and is projected to reach $136.3 billion in 2026, growing at 6.8% CAGR toward $230.7 billion by 2034. The region is expected to expand at 9.3% in 2026 — the fastest growth rate of any global region.

China alone accounts for an estimated $48.3 billion of this market in 2026, growing at 9.45% CAGR. Japan remains a mature, technology-intensive market. South Korea has built the most advanced regulatory framework for AI-enabled medical devices. Australia and Singapore offer the fastest registration pathways for manufacturers with existing FDA or EU approvals. India, Vietnam, and the broader ASEAN region represent high-growth opportunities with evolving regulatory systems.

For medical device manufacturers, APAC is no longer optional — it is a strategic imperative. But the region is not a single market. Each country has its own regulatory authority, classification system, documentation requirements, language obligations, and local representative rules. Unlike the EU, where a single CE marking provides access to 27 member states, APAC requires country-by-country registration.

This guide provides a comprehensive comparison of medical device registration requirements across the major APAC markets, maps the expanding reliance pathways that can accelerate market entry, and offers a strategic framework for prioritizing market access.

APAC Market Snapshot: Key Registration Parameters

Key observation: Every APAC market requires a local representative. Timelines range from as little as 3 months (Singapore, Australia) to over 18 months (China, Indonesia). Only Australia, India, and Singapore accept submissions in English; all other markets require local-language documentation.

Country-by-Country Registration Overview

China (NMPA)

China is the second-largest medical device market globally and the most complex APAC market for foreign manufacturers to enter. The National Medical Products Administration (NMPA) regulates devices under a three-class system (Class I, II, III).

Key requirements for imported devices:

• Local agent: Foreign manufacturers must appoint an NMPA-registered domestic agent (the China agent holds the registration certificate)
• In-country testing: Class II and III devices typically require testing at an NMPA-recognized testing laboratory in China
• Clinical evaluation: NMPA published an updated Clinical Evaluation Exemption List in May 2025; devices not on the list require clinical evaluation, which may include domestic clinical trials
• QMS: ISO 13485 certification is required; MDSAP is increasingly recognized but not a substitute for NMPA-specific QMS documentation
• UDI: NMPA has mandated UDI for Class III devices since 2022; UDI for Class II devices began phasing in from June 2024, with remaining Class II devices and IVDs subject to UDI starting June 1, 2027, with certain exemptions

2026 regulatory developments: NMPA Announcement No. 30 (2025) now allows foreign-invested enterprises to manufacture imported devices locally under their own licenses. Draft classification rules and an upcoming Medical Device Management Law will further tighten lifecycle supervision and post-market compliance.

Japan (PMDA / MHLW)

Japan operates a four-class system (Class I through IV) under the Pharmaceutical and Medical Device Act (PMD Act). The Pharmaceuticals and Medical Devices Agency (PMDA) reviews Class II–IV devices; Class I devices follow a self-declaration pathway.

Key requirements:

• Marketing Authorization Holder (MAH): Foreign manufacturers must appoint a MAH or Designated MAH (DMAH) in Japan to hold the registration
• QMS: MHLW Ordinance No. 169 (QMS requirements) applies; MDSAP is accepted as a substitute for MHLW QMS inspection for manufacturers from MDSAP-member countries
• Clinical data: Japan accepts foreign clinical data when appropriately bridged; PMDA has expanded its acceptance of clinical data from well-regulated markets
• eCTD v4.0: PMDA began accepting eCTD v4.0 submissions in 2025, modernizing the electronic submission framework
• Accelerated pathways: SAKIGAKE designation and conditional early approval are available for innovative devices addressing unmet medical needs

South Korea (MFDS)

South Korea classifies medical devices into Class I through IV under the Medical Devices Act, administered by the Ministry of Food and Drug Safety (MFDS).

Key requirements:

• Korean Good Manufacturing Practice (KGMP): Class II–IV devices require KGMP certification, which involves a facility audit by MFDS or a designated auditing body. MDSAP certification can now be used for first-time KGMP audit (effective April 2025)
• Technical documentation: MFDS requires Korean-language technical documentation, including clinical evaluation, risk management, and performance testing
• Import License Holder: Foreign manufacturers must appoint a Korean importer or license holder
• Digital Medical Products Act (DMPA): Effective 2025, South Korea established a dedicated framework for digital medical products, including SaMD and AI-enabled devices — the most advanced regulatory framework for digital health devices in APAC

Australia (TGA)

Australia's Therapeutic Goods Administration (TGA) offers one of the most efficient registration pathways in APAC for manufacturers with existing approvals from recognized regulators.

Key requirements:

• Australian Sponsor: A local sponsor (who may be the manufacturer's Australian subsidiary or a third party) holds the registration in the Australian Register of Therapeutic Goods (ARTG)
• Reliance on overseas evidence: TGA accepts conformity assessment evidence from EU Notified Bodies, FDA, Health Canada, MDSAP, and other recognized authorities. This can exempt manufacturers from a full TGA conformity assessment, saving an estimated 255 working days
• UDI: UDI requirements are being phased in, aligned with international standards
• Post-market vigilance: TGA has strengthened adverse event reporting and recall requirements

Singapore (HSA)

Singapore's Health Sciences Authority (HSA) is widely regarded as the most efficient regulatory authority in Southeast Asia and serves as a gateway for broader ASEAN market access.

Key requirements:

• Singapore Authorized Representative: A local representative must be appointed to interact with HSA
• Abridged pathways: Devices with existing approvals from FDA, EU, TGA, Health Canada, PMDA, or MFDS qualify for abridged evaluation routes with significantly shorter timelines
• ASEAN reliance hub: HSA registration serves as a reference for expedited pathways in Malaysia (via the bilateral reliance program), Thailand, the Philippines, Hong Kong, and Australia. HSA estimates that over 660 million people across ASEAN can be reached through reliance mechanisms originating from Singapore registration
• Priority review: Available for breakthrough technologies addressing unmet clinical needs

India (CDSCO)

India is the fastest-growing major medical device market in APAC, projected to reach $17.9 billion in 2026.

Key requirements:

• Classification: Class A through D (aligned with GHTF/IMDRF framework)
• Licensed authorized agent: Foreign manufacturers must appoint an Indian authorized agent
• Registration: Class C and D devices require registration with CDSCO; Class A and B devices follow a licensing pathway
• Clinical investigation: May be required for higher-risk devices; India accepts foreign clinical data in many cases
• BIS certification: Bureau of Indian Standards certification is required for certain device categories

ASEAN Markets (Malaysia, Thailand, Vietnam, Indonesia, Philippines)

The ASEAN Medical Device Directive (AMDD) provides a harmonized framework for classification (Class A–D) and CSDT (Common Submission Dossier Template) format, but implementation varies by country.

Key 2025–2026 developments:

• Singapore–Malaysia bilateral reliance: Launched September 2025, the pilot program allows devices registered with HSA to undergo verification review through Malaysia's MDA Conformity Assessment Body (CAB) in approximately 30 working days versus 60 under the standard route. The pilot ran through February 2026 and has moved to ongoing implementation
• Malaysia–Thailand bilateral reliance: A pilot ran February to April 2026 for Class B, C, and D devices, allowing Thai FDA-registered devices to access the verification route through Malaysia MDA's CAB
• China–Malaysia pilot: Malaysia also launched a pilot program accepting Class II devices approved by a provincial MPA and Class III devices approved by NMPA for IVD products manufactured in China
• Vietnam fee reduction: Vietnam halved medical device registration fees through December 2026 under Circular 64/2025/TT-BTC, reducing the cost of market entry (e.g., Class D registration dropped from VND 6,000,000 to VND 3,000,000)
• Malaysia joins MDSAP: Effective September 2025, Malaysia became an MDSAP member, expanding QMS recognition

Reliance Pathways: The Most Important Strategic Development

What Are Reliance Pathways?

Reliance pathways allow one regulatory authority to accept or leverage the assessment performed by a trusted reference authority, reducing or eliminating duplicate review. This is the single most important strategic development for manufacturers entering APAC, because it allows a single approval (typically FDA clearance or EU CE marking) to accelerate registration across multiple markets.

Reliance Pathway Map (2026)

The APACMed Regulatory Reliance Pathways Tracker provides the most current market-by-market overview. Key reliance relationships:

Strategic Implications

For manufacturers with existing FDA clearance or EU CE marking:

1. Australia is the fastest entry point — TGA's reliance on overseas evidence can reduce review time by up to 255 working days. Registration can be completed in 3–6 months.

2. Singapore is the ASEAN gateway — HSA's abridged pathway for FDA/EU-cleared devices typically completes in 3–6 months, and the resulting HSA registration can then be leveraged for Malaysia, Thailand, the Philippines, and Hong Kong.

3. Malaysia is increasingly accessible — MDA recognizes approvals from FDA, EU, TGA, Health Canada, PMDA, and HSA. The verification pathway is available for devices with existing approvals.

4. India accepts reference market data — CDSCO has expanded its acceptance of clinical data from well-regulated markets, reducing the need for domestic clinical investigations.

5. China remains the most challenging — NMPA does not participate in reliance pathways in the same way. In-country testing and potentially domestic clinical trials are still required for most Class II and III imported devices.

Market Entry Prioritization Strategy

Recommended Entry Order for Manufacturers with FDA/EU Approvals

Recommended Entry Order for Manufacturers Starting from Scratch

Cost Considerations

Registration costs in APAC vary dramatically by market and device class:

Fee basis: Government fees from official fee schedules published by each regulatory authority. Local representative and additional costs are estimates based on publicly available market data from consultancy firms and industry surveys. Actual costs vary by device type, risk class, and complexity.

Practical Tips for APAC Market Entry

1. Start with reliance pathways — If you have FDA or EU approval, leverage it. Australia and Singapore offer the fastest routes for manufacturers with existing clearances.

2. Appoint local representatives early — Every APAC market requires a local agent or representative. Selection of reliable partners is critical; they hold your registration and serve as your regulatory interface.

3. Budget for translation — China, Japan, South Korea, Thailand, Vietnam, and Indonesia all require local-language submissions. Translation costs can be significant ($10,000–$50,000 per market) and timelines should account for translation cycles.

4. Plan China and Japan early — These markets have the longest timelines (12–24 months) and the most complex requirements. Begin preparation 18–24 months before your target launch date.

5. Use the ASEAN CSDT format — The Common Submission Dossier Template allows a single core dossier to be prepared and adapted for multiple ASEAN markets, reducing documentation effort.

6. Monitor regulatory changes — APAC regulatory systems are evolving rapidly. Vietnam's fee reduction (through December 2026), Malaysia's MDSAP membership, and new bilateral reliance pilots create time-limited opportunities.

7. Consider manufacturing localization — For China, local manufacturing through a subsidiary or joint venture can reduce registration barriers, avoid some import restrictions, and improve competitiveness in public tenders. NMPA's 2025 Announcement No. 30 now facilitates this option.

For manufacturers targeting China specifically, the NMPA registration process involves unique requirements — mandatory in-country testing, Chinese-language dossier preparation, clinical evaluation obligations, and local agent management — that merit dedicated, in-depth guidance. ChinaMedGlobal, which covers NMPA registration and China medical device market-entry strategy in detail, is a useful resource for companies planning China market access.

Key Takeaways

1. APAC is a $136 billion market growing at 6.8% CAGR — it cannot be ignored in any global market access strategy.

2. Reliance pathways are the biggest opportunity — FDA or EU approval can accelerate registration in Australia, Singapore, Malaysia, and across ASEAN.

3. Every market requires a local representative — selection of reliable partners is a strategic decision, not an administrative task.

4. China and Japan remain the most complex markets — plan 18–24 months ahead and budget for in-country testing and translation.

5. ASEAN is becoming more accessible — the Singapore–Malaysia bilateral reliance program, the Malaysia–Thailand pilot, and the ASEAN CSDT format are reducing barriers to entry.

6. Market entry should be phased — start with fast-reliance markets (Australia, Singapore), then expand to larger but more complex markets (Korea, India, Japan, China).